Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Government fixed GST rate of 12 per cent on most of the essential drugs
Prices for most essential drugs will increase by as much as 2.29 percent when the goods and services tax regime starts next month. The government has set a rate of 12 percent on most essential drugs, as against the current tax incidence of around 9 per cent.
- Read more about Central approve proposal for setting up of 100 AYUSH hospitals
The Center has approved proposals for the creation of 100 Ayurveda, Unani, Siddha and Homeopathy (AYUSH) hospitals nationwide, AYUSH Minister of State Shripad Yesso Naik said.

[adsense:336x280:8701650588]
- Read more about Dr. Reddy's Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market
Dr. Reddy’s Laboratories Ltd.announced that it has launched Bivalirudin for
Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax® (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).
- Read more about Nesher Pharmaceuticals gets USFDA approval for Nystatin Topical Powder
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram.
- Read more about Cataract surgery devices sold at 10 times the market price, Maharashtra FDA report
Intraocular lenses used in cataract surgeries are being sold at a rate that is 10 times higher than the market price, Food and Drug Administration officials said in a report presented to the department of pharmaceuticals.
- Read more about Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Science, Inc. a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced that the remaining two patients in the NC1+ cohort have been dosed in the Phase 1 portion of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a devastating genetic skin disease with a high mortality rate. The cohort consists of three patients.
- Read more about Cell Design Labs announces Issuance of Broad Patent for Chimeric Notch Receptor
Cell Design Labs, Inc. announced the issuance of U.S. Patent No. 9,670,281, entitled “Binding-triggered transcriptional switches and the methods of use thereof.” This patent, issued to UC San Francisco (UCSF) and exclusively licensed to Cell Design Labs, broadly covers composition of matter for proprietary synNotch™ constructs, cells genetically modified with synNotch receptors and methods for treating diseases.
- Read more about DCGI relax guidelines for HIV paediatric drugs production
The Drug Controller General of India (DCGI) on relaxed guidelines for the production of pediatric HIV drugs, whose supply was affected by regulatory issues. The regulator approved the child-friendly and thermally stable pellet formulation of Lopinavir / Ritonavir without feasibility studies, but said it would control post-marketing surveillance.
- Read more about Zydus Cadila gets USFDA approval for Mesalamine Delayed-Release
Zydus Cadila has informed that the USFDA has given final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda® (mesalamine).
- Read more about AstraZeneca to Present Scientific Advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon (exenatide extended-release) for injectable suspension, with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA 9-13 June 2017.